The double-blind, randomised, comparator-controlled trial evaluated the effectiveness of a topical application of Levagen+ compared with a standard moisturiser to reduce eczema severity and improve patient outcomes.
Seventy-two participants aged over 18 who had redness, dry skin, scaling, and itchiness on their hands or arms were recruited.
The participants were randomly allocated to one of two treatment groups (Levagen+ or comparator).
The treatment was applied to the affected area twice daily for 4-weeks.
The researchers used the Self-Assessed Eczema Area Severity Index (SA-EASI) scoring and Patient-Oriented Eczema
Measure (POEM) from baseline to week 4 to measure the study outcomes.
The results demonstrated that Levagen+ significantly reduced redness, dryness, and total POEM score compared to a comparator cream.
“We are thrilled to share the results of this study demonstrating Levagen+’s ability to support skin health as a topical ingredient,” said R.V. Venkatesh, Co-Founder and Managing Director at Gencor.
“Supplementation with Levagen+ continues to prove just how important palmitoylethanolamide is to the body for topical and ingestible applications.”
Levagen+ is a bioavailable form of palmitoylethanolamide (PEA) with superior absorption.
Powered by the award-winning delivery technology, LipiSperse® developed by Pharmako Biotechnologies, Levagen+ has been clinically tested to support joint health, sleep, recovery, immunity, aches and discomfort, and provide a healthy inflammatory response.
Levagen+ is applicable for dietary supplements, food and beverages, and cosmeceuticals.
To review the published clinical data and for more information on Levagen+, visit www.levagenplus.com or GencorPacific.com.
